Please assess the completion status of the following clinical trial:

Trial Title: VA CoronavirUs Research and Efficacy Studies-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Veterans must meet all of the following criteria to be eligible to participate:~1. Admitted to a participating VA clinical site with symptoms suggestive of SARS-CoV-2 infection.~2. Participant (or legally authorized representative) provides informed consent prior to initiation of any study procedures.~3. Participant (or legally authorized representative) understands and agrees to comply with planned study procedures.~4. Veteran 18 years of age at time of screening.~5. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or antigen test, as documented by either of the following:~(1)Reverse Transcription polymerase chain reaction (RT-PCR) or antigen positive (nasopharyngeal, oropharyngeal, saliva, lower respiratory) in sample collected 72 hours prior to screening; (2)RT-PCR or antigen positive in sample collected \> 72 hours but 168 hours (i.e. 7 days) prior to screening, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking \> 24 hours, etc.), AND progressive disease suggestive of ongoing SARS-CoV-2 infection.~6.Requiring oxygen by nasal cannula or by face-mask as a new treatment (or if previously on home oxygen, at a liter flow at least 2 Lpm greater than home prescription), but not on humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm.~7.Can be randomized within 72 hours of hospital admission. 8.Agrees not to participate in another therapeutic clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29 without approval from the investigator(s). Taking part in other research studies, including those unrelated to SARS-CoV-2, without first discussing it with the investigators of this study may invalidate the results of this study, as well as that of the other study.~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Respiratory failure requiring mechanical ventilation, non-invasive ventilation including continuous positive airway pressure (CPAP) (for an indication other than previously diagnosed sleep apnea and maintained on outpatient settings), or extra-corporeal membrane oxygenation or anticipated to require any of those treatments or to die within 24 hours.~2. Anticipated discharge from the hospital or transfer to another hospital that is not a study site within 72 hours.~3. History of previous transfusion reaction.~4. Previously documented serum immunoglobulin A (IgA) deficiency (\<7 mg/dL)~5. Documented to have received convalescent plasma in the last 60 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma (Type: EXPERIMENTAL): The study intervention consists of intravenous administration of 200-500 mL of convalescent plasma administered in two equally divided doses, less than 12 hours apart.
- Masked Saline Placebo (Type: PLACEBO_COMPARATOR): The study intervention consists of intravenous administration of 200-500 mL of 0.9% saline administered in two equally divided doses, less than 12 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).